路透纽约12月1日 - 一名美国法官周一驳回了百时美施贵宝公司BMY.N提出的驳回一项67亿美元诉讼的请求，该诉讼声称百时美施贵宝公司欺骗了前Celgene公司的股东，推迟了包括癌症治疗药物Breyanzi在内的三种药物在规定期限内获得联邦批准的时间。
美国曼哈顿地区法官杰西-富尔曼（Jesse Furman）在驳回部分诉讼请求的同时表示，原告UMB银行可能会代表股东提出一些诉讼请求，包括违反合同。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.